Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (211-220 of 401) with videos related to

Pageof 41
Sort By:
Platelets|June 17, 2020
Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary interventionWael Sumaya, William A E Parker, Heather M Judge, et al.
European Heart Journal. Acute Cardiovascular Care|April 25, 2019
Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trialFrederic Kontny, Thomas Andersen, Thor Ueland, et al.
European Heart Journal|August 2, 2011
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomesRobert F Storey, Richard C Becker, Robert A Harrington, et al.
European Heart Journal|March 29, 2023
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleedingDavide Cao, Nicolas Amabile, Mauro Chiarito, et al.
Haematologica|May 2, 2020
Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis riskRhodri J King, Katharina Schuett, Christian Tiede, et al.
Clinical Chemistry|December 1, 2011
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes studyÅxel Akerblom, Lars Wallentin, Agneta Siegbahn, et al.
American Heart Journal|September 18, 2012
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trialJan H Cornel, Richard C Becker, Shaun G Goodman, et al.
Journal of the American Heart Association|March 13, 2019
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y<sub>12</sub> Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO TrialFrancesco Franchi, Stefan K James, Tatevik Ghukasyan Lakic, et al.
Circulation|June 29, 2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trialKenneth W Mahaffey, Daniel M Wojdyla, Kevin Carroll, et al.
Journal of the American College of Cardiology|May 7, 2011
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudyBenjamin M Scirica, Christopher P Cannon, Håkan Emanuelsson, et al.
Pageof 41

Showing results (211-220 of 401) with videos related to

Sort By:
Pageof 41
Platelets|June 17, 2020
Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary interventionWael Sumaya, William A E Parker, Heather M Judge, et al.
European Heart Journal. Acute Cardiovascular Care|April 25, 2019
Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trialFrederic Kontny, Thomas Andersen, Thor Ueland, et al.
European Heart Journal|August 2, 2011
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomesRobert F Storey, Richard C Becker, Robert A Harrington, et al.
European Heart Journal|March 29, 2023
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleedingDavide Cao, Nicolas Amabile, Mauro Chiarito, et al.
Haematologica|May 2, 2020
Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis riskRhodri J King, Katharina Schuett, Christian Tiede, et al.
Clinical Chemistry|December 1, 2011
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes studyÅxel Akerblom, Lars Wallentin, Agneta Siegbahn, et al.
American Heart Journal|September 18, 2012
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trialJan H Cornel, Richard C Becker, Shaun G Goodman, et al.
Journal of the American Heart Association|March 13, 2019
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y<sub>12</sub> Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO TrialFrancesco Franchi, Stefan K James, Tatevik Ghukasyan Lakic, et al.
Circulation|June 29, 2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trialKenneth W Mahaffey, Daniel M Wojdyla, Kevin Carroll, et al.
Journal of the American College of Cardiology|May 7, 2011
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudyBenjamin M Scirica, Christopher P Cannon, Håkan Emanuelsson, et al.
Pageof 41